Litouwen - Litouws - SMCA (Valstybinė vaistų kontrolės tarnyba)

us pharmacia sp. z o.o. - aliuminio hidroksidas/magnio hidroksidas/simetikonas - kramtomosios tabletės - 200 mg/200 mg/25 mg - combinations

Litouwen - Litouws - SMCA (Valstybinė vaistų kontrolės tarnyba)

zakłady farmaceutyczne polpharma s.a. - ksilometazolino hidrochloridas/dekspantenolis - nosies purškalas (tirpalas) - 0,5 mg/50 mg/ml - xylometazoline

Litouwen - Litouws - SMCA (Valstybinė vaistų kontrolės tarnyba)

zakłady farmaceutyczne polpharma s.a. - ksilometazolino hidrochloridas/dekspantenolis - nosies purškalas (tirpalas) - 1 mg/50 mg/ml - xylometazoline

Litouwen - Litouws - SMCA (Valstybinė vaistų kontrolės tarnyba)

sia elvim - latanoprostas - akių lašai (tirpalas) - 50 µg/ml - latanoprost

Europese Unie - Litouws - EMA (European Medicines Agency)

sanofi winthrop industrie - dupilumabas - dermatitis, atopic; prurigo; esophageal diseases; asthma; sinusitis - dermatito veikėjai, išskyrus kortikosteroidus - atopic dermatitisadults and adolescentsdupixent is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy. children 6 months to 11 years of agedupixent is indicated for the treatment of severe atopic dermatitis in children 6 months to 11 years old who are candidates for systemic therapy. asthmaadults and adolescentsdupixent is indicated in adults and adolescents 12 years and older as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (feno), see section 5. 1, who are inadequately controlled with high dose inhaled corticosteroids (ics) plus another medicinal product for maintenance treatment. children 6 to 11 years of agedupixent is indicated in children 6 to 11 years old as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (feno), who are inadequately controlled with medium to high dose inhaled corticosteroids (ics) plus another medicinal product for maintenance treatment. chronic rhinosinusitis with nasal polyposis (crswnp)dupixent is indicated as an add-on therapy with intranasal corticosteroids for the treatment of adults with severe crswnp for whom therapy with systemic corticosteroids and/or surgery do not provide adequate disease control. prurigo nodularis (pn)dupixent is indicated for the treatment of adults with moderate-to-severe prurigo nodularis (pn) who are candidates for systemic therapy. eosinophilic esophagitis (eoe)dupixent is indicated for the treatment of eosinophilic esophagitis in adults and adolescents 12 years and older, weighing at least 40 kg, who are inadequately controlled by, are intolerant to, or who are not candidates for conventional medicinal therapy.

Litouwen - Litouws - SMCA (Valstybinė vaistų kontrolės tarnyba)

cefak kg - ginkgo biloba urtinktūra/viscum album urtinktūra/crataegus urtinktūra - geriamieji lašai (tirpalas) - 13,3 mg/27,6 mg/76,5 mg/ml

Litouwen - Litouws - SMCA (Valstybinė vaistų kontrolės tarnyba)

stada arzneimittel ag - doksiciklinas - tabletės - 100 mg; 200 mg - doxycycline

Litouwen - Litouws - SMCA (Valstybinė vaistų kontrolės tarnyba)

fresenius kabi deutschland gmbh - izoleucinas/leucinas/lizinas/metioninas/cisteinas/fenilalaninas/treoninas/triptofanas/valinas/argininas/histidinas/glicinas/alaninas/prolinas/serinas/acto rūgštis, ledinė - infuzinis tirpalas - 10,4 g/13,09 g/6,88 g/1,1 g/0,52 g/0,88 g/4,4 g/0,7 g/10,08 g/10,72 g/2,8 g/5,82 g/4,64 g/5,73 g/2,24 g/4,42 g/1000 ml - amino acids

Europese Unie - Litouws - EMA (European Medicines Agency)

biomarin international limited - sapropterin dihidrochloridas - phenylketonurias - kiti virškinimo trakto ir metabolizmo produktus, - kuvan skiriamas hiperfenilalaninemijos (hpa) gydymui suaugusiems žmonėms ir visų amžiaus grupių vaikams, sergantiems fenilketonurija (pku), kuriems buvo reaguojama į tokį gydymą. kuvan taip pat nurodė, gydymo hyperphenylalaninaemia (hpa) suaugusiųjų ir vaikų pacientams visose amžiaus su tetrahydrobiopterin (bh4) trūkumų, kurie buvo įrodyta, kad būtų reaguojama į tokį gydymą.

Europese Unie - Litouws - EMA (European Medicines Agency)

novartis europharm limited - nepafenac - pain, postoperative; ophthalmologic surgical procedures - oftalmologai - nevanac is indicated for: , prevention and treatment of postoperative pain and inflammation associated with cataract surgery;, reduction in the risk of postoperative macular oedema associated with cataract surgery in diabetic patients.